Cao, Lejie
University of Science and Technology of China · Anhui Provincial Hospital
2 papers on CoChat
Most cited papers
- Verified
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2021) · The Lancet Respiratory Medicine
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 483
- Verified
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 23
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free